Marilyn A Huestis

发表

Modern instrumental methods in forensic toxicology.

Michael L Smith, Shawn P Vorce, Justin M Holler, 2007, Journal of analytical toxicology.

Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids.

Marilyn A Huestis, Simona Pichini, Francesco P Busardò, 2019, Therapeutic drug monitoring.

Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine Administration

Marilyn A Huestis, Elliot A Stein, E. Stein, 2008, Journal of clinical psychopharmacology.

Cannabis effects on driving skills.

Marilyn A Huestis, M. Huestis, R. Hartman, 2013, Clinical chemistry.

Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.

Marilyn A Huestis, M. Huestis, D. Gorelick, 2009, Journal of analytical toxicology.

Modern analytical technologies for the detection of drug abuse and doping.

Marilyn A Huestis, M. Huestis, Michael L Smith, 2006, Drug discovery today. Technologies.

Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry

Marilyn A Huestis, M. Huestis, Michael J. Y. Jarvis, 2014, Analytical and Bioanalytical Chemistry.

Oral fluid testing for drugs of abuse.

Marilyn A Huestis, W. M. Bosker, M. Huestis, 2009, Clinical chemistry.

Cognitive Measures in Long‐Term Cannabis Users

Marilyn A Huestis, Deborah Yurgelun-Todd, D. Yurgelun-Todd, 2002, Journal of clinical pharmacology.

Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients.

Marilyn A Huestis, H. Jones, W. Lambert, 2007, Drug and alcohol dependence.

Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching.

Marilyn A Huestis, Robert Kronstrand, M. Castaneto, 2015, Journal of chromatography. A.

First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

Marilyn A Huestis, Mingshe Zhu, M. Huestis, 2013, Clinical chemistry.

Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis.

Marilyn A Huestis, Edward J Cone, M. Huestis, 2004, Journal of analytical toxicology.

Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Marilyn A Huestis, W. M. Bosker, J. Ramaekers, 2012, Journal of analytical toxicology.

Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search.

Marilyn A Huestis, M. Huestis, Xiao‐hong Chen, 2013, Analytical chemistry.

Interpretation of Oral Fluid Tests for Drugs of Abuse

Marilyn A Huestis, Edward J Cone, M. Huestis, 2007, Annals of the New York Academy of Sciences.

Prenatal and postnatal cocaine exposure predict teen cocaine use.

Marilyn A Huestis, Joel Ager, James Janisse, 2011, Neurotoxicology and teratology.

CB1 – Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men

Marilyn A Huestis, Denis Bonnet, Deanna L Kelly, 2012, The American journal of drug and alcohol abuse.

Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Marilyn A Huestis, M. Castaneto, Nathalie A. Desrosiers, 2014, Drug and alcohol dependence.

Simultaneous quantification of Δ(9)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry.

Marilyn A Huestis, M. Huestis, M. Concheiro, 2013, Journal of chromatography. A.

Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration.

Marilyn A Huestis, Edward J Cone, M. Huestis, 2006, Journal of analytical toxicology.